ROIVANT SCIENCES LTD (ROIV)
BMG762791017 - Common Stock
ROIV gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 587 industry peers in the Biotechnology industry. ROIV scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ROIV is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year ROIV has reported negative net income.
ROIV had a negative operating cash flow in the past year.
In the past 5 years ROIV reported 4 times negative net income.
ROIV had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of ROIV (61.08%) is better than 100.00% of its industry peers.
ROIV's Return On Equity of 73.34% is amongst the best of the industry. ROIV outperforms 99.66% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 61.08% | ||
| ROE | 73.34% | ||
| ROIC | N/A |
ROA(3y)-35.39%
ROA(5y)N/A
ROE(3y)-61.06%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 3624.16%, ROIV belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
Looking at the Gross Margin, with a value of 87.57%, ROIV belongs to the top of the industry, outperforming 91.28% of the companies in the same industry.
In the last couple of years the Gross Margin of ROIV has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 3624.16% | ||
| GM | 87.57% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7.2%
GM growth 5YN/A
2. Health
2.1 Basic Checks
ROIV does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ROIV has been increased compared to 1 year ago.
Compared to 1 year ago, ROIV has a worse debt to assets ratio.
2.2 Solvency
An Altman-Z score of 5.29 indicates that ROIV is not in any danger for bankruptcy at the moment.
ROIV has a better Altman-Z score (5.29) than 80.00% of its industry peers.
ROIV has a Debt/Equity ratio of 0.07. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.07, ROIV is not doing good in the industry: 62.22% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 5.29 |
ROIC/WACCN/A
WACC8.43%
2.3 Liquidity
ROIV has a Current Ratio of 27.79. This indicates that ROIV is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 27.79, ROIV belongs to the best of the industry, outperforming 97.09% of the companies in the same industry.
ROIV has a Quick Ratio of 27.77. This indicates that ROIV is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 27.77, ROIV belongs to the best of the industry, outperforming 97.09% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 27.79 | ||
| Quick Ratio | 27.77 |
3. Growth
3.1 Past
ROIV shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 22.89%, which is quite impressive.
ROIV shows a strong growth in Revenue. In the last year, the Revenue has grown by 185.81%.
Measured over the past years, ROIV shows a decrease in Revenue. The Revenue has been decreasing by -3.26% on average per year.
EPS 1Y (TTM)22.89%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q38.78%
Revenue 1Y (TTM)185.81%
Revenue growth 3Y-3.26%
Revenue growth 5YN/A
Revenue growth Q2Q117.83%
3.2 Future
The Earnings Per Share is expected to grow by 18.79% on average over the next years. This is quite good.
Based on estimates for the next years, ROIV will show a very strong growth in Revenue. The Revenue will grow by 89.20% on average per year.
EPS Next Y385.55%
EPS Next 2Y9.5%
EPS Next 3Y7.84%
EPS Next 5Y18.79%
Revenue Next Year147.65%
Revenue Next 2Y74.06%
Revenue Next 3Y83.39%
Revenue Next 5Y89.2%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ROIV. In the last year negative earnings were reported.
Also next year ROIV is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.5%
EPS Next 3Y7.84%
5. Dividend
5.1 Amount
ROIV does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ROIVANT SCIENCES LTD
NASDAQ:ROIV (5/16/2024, 1:30:09 PM)
11.4
-0.1 (-0.87%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap9.19B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 61.08% | ||
| ROE | 73.34% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | 3624.16% | ||
| GM | 87.57% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.02
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 27.79 | ||
| Quick Ratio | 27.77 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)22.89%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y385.55%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)185.81%
Revenue growth 3Y-3.26%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y